Plain-English translation of NCT04123314 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage pilot study testing whether can help reduce depression in people who have been diagnosed with mild cognitive impairment or early Alzheimer's disease. is a naturally occurring compound that researchers believe may help improve mood and quality of life. The study will track changes in depression symptoms and overall quality of life over 6 months.
Depression is common in people with early memory loss, but current antidepressant medications don't work well for everyone. Researchers want to see if this medication might offer a new treatment option for people struggling with both cognitive decline and depression.
You likely qualify if…
You likely don't qualify if…
You would take part in an 8-week program that includes weekly psychological support sessions with a trained therapist. You would receive two doses of the medication — one in week 4 and another in week 6 — in a carefully controlled clinical setting. After your final dose, you would have follow-up appointments over the next 6 months so researchers can track any changes in your mood and quality of life.
AI-generated summary from trial data · Oct 4, 2026 · Not medical advice
United States